Combined effects of tirapazamine and mild hyperthermia on anti- angiogenic agent (TNP-470) treated tumors - Reference to the effect on intratumor quiescent cells

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 3, 2000, Pages 799-807

  Masunaga, Shin Ichiro ^a   Ono, Koji ^a   Nishimura, Yasumasa ^b   Kanamori, Shuichi ^a   Saga, Tsuneo ^a   Suzuki, Minoru ^b   Kinashi, Yuko ^a   Takagaki, Masao ^a   Kasai, Soko ^c   Nagasawa, Hideko ^c   Uto, Yoshihiro ^c   Hori, Hitoshi ^c  

^a KYOTO UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Hypoxic fraction; Labeling index; Mild hyperthermia; Quiescent cell; Tirapazamine; TNP 470

Indexed keywords

BROXURIDINE; CISPLATIN; CYTOCHALASIN B; FUMAGILLOL CHLOROACETYLCARBAMATE; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; GAMMA IRRADIATION; HYPERTHERMIC THERAPY; LABELING INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOHEXANES; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTHERMIA, INDUCED; MICE; MICE, INBRED C3H; MICRONUCLEUS TESTS; RADIATION-SENSITIZING AGENTS; REGRESSION ANALYSIS; SESQUITERPENES; TRIAZINES;

EID: 0034212339     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00477-6     Document Type: Article

References (34)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:1990;4-6.
2. Gervas P., Fontolliet C. Therapeutic potential of the anti-angiogenesis drug TNP-470. Int J Exp Pathol. 79:1998;359-362.
3. Brown J.M., Giaccia A.J. The unique physiology of solid tumors Opportunities (and problems) for cancer therapy . Cancer Res. 58:1998;1408-1416.
4. Brem H., Ingber D., Blood C.H., et al. Suppression of tumor metastasis by angiogenesis inhibition. Surg Forum. 42:1991;439-441.
5. Ingber D., Fujita T., Kishimoto S., et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 348:1990;555-557.
6. Kusaka M., Sudo K., Fujita T., et al. Potent antiangiogenic action of AGM-1470 comparison to the fumagillin parent . Biochem Biophys Res Commun. 174:1991;1070-1076.
7. Brem H., Folkman J. Analysis of experimental antiangiogenic therapy. J Pediatr Surg. 28:1993;445-451.
8. Brem H., Gresser I., Grosfeld J., et al. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg. 28:1993;1253-1257.
9. Kusaka M., Sudo K., Matsutani E., et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer. 69:1994;212-216.
10. Yanase T., Tamura M., Fujita K., et al. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. 53:1993;2566-2570.
11. Teicher B.A., Holden S.A., Ara G., et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma Oxygenation and response to cytotoxic therapy . Int J Cancer. 61:1995;732-737.
12. Kakeji Y., Teicher B.A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drug. 15:1997;39-48.
13. Yamaoka M., Yamamoto T., Ikeyama S., et al. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostatic carcinoma cell lines. Cancer Res. 53:1993;5233-5236.
14. Teicher B.A., Depuis N.P., Kusumoto T., et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest. 2:1995;269-276.
15. Nishimura Y., Murata R., Hiraoka M. Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Br J Cancer. 73:1996;270-276.
16. Rauth A.M., Melo T., Misra V. Bioreductive therapies An overview of drugs and their mechnisms of action . Int J Radiat Oncol Biol Phys. 42:1998;755-762.
17. Zeman E.M., Brown J.M., Lemmon M.J., et al. SR-4233 A new bioreductive agent with high selective toxicity for hypoxic mammalian cells . Int J Radiat Oncol Biol Phys. 12:1986;1239-1242.
18. Murata R., Nishimura Y., Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys. 37:1997;1107-1113.
19. Masunaga S., Ono K., Hori H., et al. Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide Reference to effect on quiescent tumour cells . Int J Hyperthermia. 15:1999;7-16.
20. Masunaga S., Ono K., Abe M. Potentially lethal damage repair by quiescent cells in murine solid tumors. Int J Radiat Oncol Biol Phys. 22:1992;973-978.
21. Seng F., Ley K. Simple synthesis of 3-amino-1,2,4-benzotriazine-1,4-dioxide. Angew Chem Int Ed Engl. 11:1972;1009-1010.
22. Nishimura Y., Shibamoto Y., Jo S., et al. Relationship between heat-induced vascular damage and thermosensitivity in four mouse tumors. Cancer Res. 48:1988;7226-7230.
23. Brown J.M., Lemmon M.J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50:1990;7745-7749.
24. Dorie M.J., Brown J.M. Tumor-specific, schedule dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53:1993;4633-4636.
25. Masunaga S., Ono K., Akaboshi M., et al. Augmentation in chemosensitivity of intratumor quiescent cells by combined treatment with nicotinamide and mild hyperthermia. Jpn J Cancer Res. 88:1997;770-777.
26. Ono K., Wandl E.O., Tsutsui K., et al. The correlation between cell survival curve and dose response curve of micronucleus (MN) frequency. Strahlenther Onkol. 165:1989;824-827.
27. Prados M.D., Scott C.B., Rotman M., et al. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma . Int J Radiat Oncol Biol Phys. 40:1998;653-659.
28. Moulder J.E., Rockwell S. Hypoxic fractions of solid tumors experimental techniques, methods of analysis, and a survey of existing data . Int J Radiat Oncol Biol Phys. 10:1984;695-712.
29. Fenech M., Morley A.A. Measurement of micronuclei in lymphocytes. Mutat Res. 147:1985;29-36.
30. Koch C.J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 53:1993;3992-3997.
31. Nishimura Y., Ono K., Hiraoka M., et al. Treatment of murine SCC VII tumors with localized hyperthermia and temperature-sensitive liposomes containing cisplatin. Radiat Res. 122:1990;161-167.
32. Dewey W.C. Arrhenius relationship from the molecule and to clinic. Int J Hyperthermia. 10:1994;457-483.
33. Kanamori S., Nishimura Y., Okuno Y., et al. Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor. Int J Hyperthermia. 15:1999;267-278.
34. Wouters B.G., Brown J.M. Cell at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res. 147:1997;541-550.